Recent trends in cutaneous malignant melanoma in the Yorkshire region of England; incidence, mortality and survival in relation to stage of disease, 1993–2003

The aim of this study was to investigate recent trends in incidence, mortality and survival in patients diagnosed with malignant melanoma (MM) in relation to stage (Breslow thickness). Cases of primary invasive and in situ MM diagnosed between 1st January 1993 and 31st December 2003 in the former Yorkshire Health Authority were identified from cancer registry data. Over the study period, the incidence of invasive MM increased from 5.4 to 9.7 per 100 000 in male subjects and from 7.5 to 13.1 per 100 000 in female subjects. Most of this increase was seen in thin tumours (<1.5 mm). Thin tumours were more likely to be diagnosed in the younger age groups and be classified as superficial spreading melanoma. In situ melanoma rates increased only slightly. Over the same time period, mortality rates have been relatively constant in both male and female subjects. Five-year relative survival varied from 91.8% (95% CI 90.4–93.1) for patients with thin tumours to 41.5% (95% CI 36.7–46.3) for those with thick tumours. In multivariable analyses, Breslow thickness was the most important prognostic factor. Age, sex and level of deprivation were also identified as independent prognostic factors. The trends in incidence suggest that the increase is real, rather than an artefact of increased scrutiny, implying that primary prevention in the Yorkshire area of the UK has failed to control trends in incidence. Mortality, in contrast, appears to be levelling off, indicating that secondary prevention has been more effective.

[1]  D. Roberts,et al.  Malignant melanoma in South Wales: changing trends in presentation (1986–98) , 2001, Clinical and experimental dermatology.

[2]  E. Wilkinson Cancer Research UK , 2002 .

[3]  D. Miller,et al.  Update on the incidence and mortality from melanoma in the United States. , 1999, Journal of the American Academy of Dermatology.

[4]  Lisa M. Schwartz,et al.  Skin biopsy rates and incidence of melanoma: population based ecological study , 2005, BMJ : British Medical Journal.

[5]  J. Melia,et al.  Cancer Research Campaign health education programme to promote the early detection of cutaneous malignant melanoma. II. Characteristics and incidence of melanoma , 1995, The British journal of dermatology.

[6]  F. Bray,et al.  Monitoring stage-specific trends in melanoma incidence across Europe reveals the need for more complete information on diagnostic characteristics , 2004, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

[7]  F. Ederer,et al.  The relative survival rate: a statistical methodology. , 1961, National Cancer Institute monograph.

[8]  J. Stockman,et al.  Distinct Sets of Genetic Alterations in Melanoma , 2007 .

[9]  R. Burton,et al.  Recent incidence trends imply a nonmetastasizing form of invasive melanoma , 1994, Melanoma research.

[10]  D. Stockton,et al.  Thick melanoma: the challenge persists , 2005, The British journal of dermatology.

[11]  F. Bray,et al.  Changing epidemiology of malignant cutaneous melanoma in Europe 1953–1997: Rising trends in incidence and mortality but recent stabilizations in Western Europe and decreases in Scandinavia , 2003, International journal of cancer.

[12]  M. Nicolson,et al.  Incidence of and survival from malignant melanoma in Scotland: an epidemiological study , 2002, The Lancet.

[13]  M. Berwick Why are people still dying from melanoma? , 1999, Archives of dermatology.

[14]  Brämer Gr International statistical classification of diseases and related health problems. Tenth revision. , 1988, World health statistics quarterly. Rapport trimestriel de statistiques sanitaires mondiales.

[15]  D. Hole,et al.  Incidence and thickness of primary tumours and survival of patients with cutaneous malignant melanoma in relation to socioeconomic status , 1996, BMJ.

[16]  B. Armstrong,et al.  Trends in the incidence of cutaneous malignant melanoma in New South Wales, 1983–1996 , 2001, International journal of cancer.

[17]  J. Coebergh,et al.  Melanoma incidence has risen in Europe , 2005, BMJ : British Medical Journal.

[18]  J. Hunter,et al.  Incidence, mortality and survival in cutaneous malignant melanoma in Scotland 1979???1994: 260 , 1997 .

[19]  J. Coebergh,et al.  Cutaneous malignant melanoma in Europe. , 2004, European journal of cancer.

[20]  H. Møller,et al.  Trends in the incidence of cutaneous malignant melanomas in the south east of England, 1960-1998. , 2002, Journal of public health medicine.

[21]  J. Hunter,et al.  Cutaneous malignant melanoma in Scotland: incidence, survival, and mortality, 1979-94 , 1997, BMJ.

[22]  R. Swerlick,et al.  The melanoma epidemic. Is increased surveillance the solution or the problem? , 1996, Archives of dermatology.

[23]  Suephy C. Chen,et al.  The melanoma epidemic : Is increased surveillance the solution or the problem ? , 1996 .

[24]  J. Fridlyand,et al.  Distinct sets of genetic alterations in melanoma. , 2005, The New England journal of medicine.